We hypothesized that peptidoglycan (PG) fragments decrease appetite in rats. Male Lewis rats (150 g; n 2 7) received intraperitoneal (i.p.) injections of purified soluble PG fragments that had been treated with polymyxin B-agarose to remove residual endotoxin. Food consumption and body weight gain were determined at intervals after injection. Single i.p. injections of macromolecular extensively O-acetylated PG (S-O-PG) and non-O-acetylated PG fragments (24 to 240 ,ug/kg) reduced food intake and body weight gain in a dosedependent fashion during the first 12 h after injection. Low-molecular-weight disaccharide peptide monomers with nonreducing 1,6-anhydro-N-acetylmuramic acid ends and muramyl dipeptide (MDP; 1.6 mg/kg) were also appetite and weight gain suppressants, albeit at least 10-fold less potent than S-O-PG; however, muramidasederived monomers and peptide cross-linked dimers with reducing muramic acid ends were inactive. Appetite suppression was not limited to the Lewis rat strain since another strain, F344, exhibited similar decreases in food intake after injection of S-O-PG or MDP. Oral administration of MDP or S-O-PG, at concentrations 3 and 20 times higher, respectively, than those that were active i.p., failed to elicit a hypophagic response. We conclude that soluble PG fragments are potent suppressants of food consumption and body weight gain in rats and that, although macromolecular PG is more potent than low-molecular-weight fragments, neither O-acetylation nor glycosidic linkage of PG fragments is required for activity. We speculate that PG fragments may contribute to loss of appetite during bacterial illness.
It is universally recognized that classic features of infectious illness include fever, increased sleepiness, and decreased appetite. These symptoms, together with other manifestations of the acute-phase response, are attributed to the release of the host's endogenous inflammatory cytokines such as the interleukins and tumor necrosis factor (49) . Indeed, interleukin-1 (IL-1), a well-known endogenous pyrogen (7, 11) , and tumor necrosis factor, a putative pyrogen (8, 35) and cryogen (16) , possess somnogenic and/or anorectic effects when administered parenterally (24, 31, 32, 36, 44, 52) .
Lipopolysaccharide (LPS), a unique component of gramnegative outer membranes, and muramyl dipeptide (MDP; adjuvant peptide), the minimal structure in Freund's complete adjuvant that retains immunomodulatory activity (10) and a synthetic component derived from the peptidoglycan (PG) of bacterial cell walls, induce fever (9, 38) , enhance slow-wave sleep (20, 22) , and decrease food intake (26, 30, 53) . Since LPS and MDP stimulate the release of cytokines both in vivo (4, 38) and in vitro (6, 9) , it is presumed that these bacterial components modulate appetite, sleep, and fever by triggering the release of the host's endogenous cytokines, which, in turn, mediate the response (21) .
We hypothesized that naturally occurring PG fragments released from bacterial cell walls might contribute to the decrease in food consumption observed during bacterial illness. Indeed, on the basis of in vitro studies, it is likely that a large variety of PG fragments are released from intact bacteria in vivo by the action of bacterial PG-degrading enzymes that function in cell division (40, 48) as well as by host-derived PG hydrolases, such as lysozyme (2, 43) . These physiologically realistic PG fragments, composed of alternating units of N-acetylglucosamine and N-acetylmuramic acid (NAM) with a short peptide attached to the lactyl group of the NAM residue, range in size from submonomeric particles of <500 Da to enormous soluble macromolecules of >106 Da (43) . PG fragments induce numerous biological effects (13, 17) , including pyrogenicity (28, 29) and somnogenicity (19, 27) . Furthermore, PG fragments stimulate the release of IL-1 in vitro (34) ; hence, we investigated the ability of purified, naturally occurring PG fragments to decrease appetite in a rat model. Other laboratories have assessed the hypophagic effects of various agents during daytime rather than nighttime hours by fasting experimental animals or by reversing the light-dark cycles of the animals. We believe our experimental model, in which bacterial cell wall components are administered just prior to the onset of darkness, the time during which rats consume approximately 85% of their diet, is more physiologically realistic since it permits access to food and water ad libitum and maintains the normal circadian rhythms of the rats.
MATERIALS AND METHODS
Preparation of bacterial cell wall components. Soluble 0-acetylated peptidoglycan (S-0-PG) and non-0-acetylated peptidoglycan (S-non-O-PG) fragments were obtained by sonication of intact PG purified from Neisseria gonorrhoeae FA19 and RD5, respectively, as described previously (41) . Monomeric and dimeric PG fragments containing reducing NAM ends were purified as described previously (41) significantly greater than that to the intermediate concentration (P < 0.05).
The hypophagic response to PG occurred within the first 12 h after injection and was apparently of short duration since the PG-injected animals consumed food in amounts indistinguishable from control animals during the daylight phase, 12 to 24 h postinjection (data not shown), and the ensuring 12-h dark phase (Fig. 1A) .
The effect of PG on food consumption was, as expected, accompanied by a corresponding dose-dependent decrease in body weight gain. S-O-PG (240 and 24 ,ug/kg) decreased body weight gain in rats by 64 and 35%, respectively, compared with the saline-injected controls (P < 0.05) (Fig. 1B) , whereas the lowest dose tested (2.4 jig/kg) had no significant effect. Data presented in Fig. 1 cyte lysate assay. In our experience, the lowest dose of LPS which significantly decreased food consumption was 10 jig/kg (P < 0.05 versus saline control) (Fig. 2) . The amount of Limulus assay-reactive material in preparations of S-0-PG was equivalent to a concentration of 1 ng of endotoxin per 15 ,ug of S-0-PG or less. It should be emphasized that this figure probably represents a gross overestimation of endotoxin contamination since S-0-PG itself is positive in the Limulus assay (18) . In fact, the Limulus assay reactivity of other S-0-PG preparations is reduced by as much as 90% upon digestion of the glycan backbone with PG-specific muramidases (41) . Thus, even if all Limulus-reactive material in the S-0-PG preparations was due to contaminating LPS, the level of LPS would be less than 1/1,000 of the amount necessary for LPS alone to decrease appetite.
Rats do not compensate for PG-mediated hypophagia. To determine if rats compensate for decreased caloric intake by overeating subsequent to PG-induced hypophagia, food consumption was monitored for 10 days after injection of S-0-PG (240 ,ug/kg) in one experiment. As in previous experiments, PG-injected rats decreased food intake immediately after administration but resumed normal food intake by 24 h postinjection. At no time during the 10-day observation period did PG-treated rats consume more than the saline-injected rats (Fig. 3) ; hence, rats did not compensate for lost calories by rebound hyperphagia.
O-Acetylation of PG is not required for hypophagic response. S-O-PG preparations, as employed in experiments discussed so far, possess 0-acetyl derivatives on C-6 of about 50% of the NAM residues (51). This chemical configuration of PG has been associated with resistance to degradation by PG hydrolases (43, 51) and increased potency in some biological activities, including arthritogenicity (12, 42) and stimulation of IL-1 release (37); thus, we hypothesized that S-0-PG might be a more potent appetite suppressant than S-non-O-PG. The data suggested, however, that O-acetylation of PG is not necessary for hypophagia in rats (Table 1) . At concentrations of 240 and 24 ,ug/kg, both S-0-PG and S-non-O-PG decreased food intake and body weight gain compared with saline controls (P < 0.05), but the effects of S-0-PG and S-non-O-PG did not differ significantly from each other. These results were confirmed in two additional experiments.
Low-molecular-weight PG fragments are appetite suppressants. The previous experiments, all utilizing soluble macromolecular PG fragments, support the hypothesis that PG contributes to the hypophagia frequently observed during bacterial illness; however, since many physiologically realistic PG fragments are of low molecular weight, we assessed the effects of dimeric, monomeric, and submonomeric PG fragments on food consumption and body weight gain. Reducing un-cross-linked disaccharide peptide monomers and peptide cross-linked dimers (1.6 mg/kg), prepared by using Chalaropsis B muramidase, had no effect on food consumption, whereas the 1,6-anhydro-NAM-containing monomers and MDP (1.6 mg/kg) both reduced food intake by approximately 25% compared with controls (P < 0.05) ( Table 2) . Similarly, PG dimers and monomers, prepared with Chalaropsis B muramidase, had no effect on body weight gain, while 1,6-anhydro-NAM-containing monomers and MDP decreased weight gain by greater than 50% (P < 0.05) ( Table 2 ). Data presented are from one experiment; the differential ability of the PG fragments to reduce food consumption was confirmed in two additional experiments. Endotoxin contamination in 1,6-anhydro-NAMcontaining monomer preparations was less than 1 ng/400 ,ug of monomer; in MDP preparations, contaminating endotoxin was present at less than the detection limit of 1 ng/2 mg of MDP. These concentrations of contaminating endotoxin are 2,500 and 12,500 times less, respectively, than the minimum hypophagic dose of LPS (Fig. 2) . PG is hypophagic in both F344 and Lewis rats. The F344 rat strain has been shown to be relatively resistant to PG-induced arthritis in an in vivo model in comparison with the Lewis rat strain (1, 55) . Further, thioglycolate-elicited peritoneal macrophages from F344 rats produce significantly less IL-1 in vitro than do peritoneal macrophages from Lewis rats when stimulated by PG (37) . Thus, we hypothesized that F344 rats might be relatively resistant to the hypophagic effects of PG. However, S-0-PG (240 and 24 p,g/kg) and MDP (1.6 mg/kg) decreased food consumption in both F344 and Lewis rats compared with saline controls (P < 0.05) ( Table 3) and, at the doses tested, did so to similar extents. As expected, the decrease in food consumption in both rat strains was accompanied by a decrease in weight gain, in comparison with saline controls (P < 0.05) ( Table 3) .
PG fragments do not suppress food intake after oral administration. We determined if PG fragments could decrease food consumption and body weight gain after oral administration. Doses of S-0-PG and MDP as high as 5.0 mg/kg had no effect on rat food intake or weight gain (data not shown) when administered intragastrically by using a stainless-steel feeding needle inserted through the oral cavity. However, the same preparations of S-0-PG and MDP at concentrations of 250 and 1.6 mg/kg, respectively, resulted in significant decreases in food consumption when injected i.p. just as other preparations (Fig. 1A and however, it is now clear that PG is a potent biological effector both in vivo and in vitro (13) . Within the last 20 years, it was noted that PG possesses other activities, e.g., pyrogenicity (28, 29) and somnogenicity (19, 27) , suggesting that PG impacts central nervous system function in addition to its well-documented effects on the immune system. PG may evoke fever and sleep via an IL-1-mediated mechanism, since IL-1 is known to be both pyrogenic (7) and somnogenic (24) and since PG induces release of IL-1 from macrophages (34) and glial cells (37) . Herein, we report another bioactivity of PG, suppression of appetite, that is normally controlled centrally. The data suggest that S-0-PG decreases food intake and body weight gain in rats dose dependently after a single i.p. injection. The effect is of relatively short duration, evident during the first 12 h after injection but not thereafter. Rats do not compensate for loss of caloric intake by overeating once the hypophagic effect of PG subsides.
Chemical modification of the glycosidic PG backbone by 0-acetylation of the C-6 of the NAM residues seems to confer resistance to enzymatic degradation of PG (43) and is associated with maximum potency of PG for some bioactivities (12, 42) . Hence, we hypothesized that S-0-PG would be a more potent appetite suppressant than S-non-O-PG; however, both configurations of PG fragments decreased food intake to the same extent. One explanation is that the hypophagic effect of PG is initiated shortly after administration such that appetite suppression is signaled before PG degradation occurs. Alternatively, one might hypothesize that if the bioactive component of the PG preparations is a low-molecular-weight product of PG degradation, the S-non-O-PG would be more potent than the S-0-PG since it is more readily digested in vitro; however, our data do not support this theory either. In fact, further experiments exploiting our inventory of PG monomers and dimers argue that low-molecular-weight PG fragments are less potent than macromolecular PG on both a weight and a molar basis.
Only two of the four low-molecular-weight fragments tested display hypophagic potential in the rat. The 1,6-anhydro-NAM-containing monomers and MDP, both previously documented to be potent somnogens (23, 25) , are effective appetite suppressants; hence, glycosidic linkage is not required for hypophagic effect. However, neither reducing un-cross-linked disaccharide peptide monomers, documented to be active somnogens (14, 19) , arthritogens (12) , and IL-1 inducers (37), nor peptide cross-linked dimers are active. It is not surprising that the latter do not suppress appetite since peptide crosslinked dimers have been inactive in all biological activities tested thus far, but it is presently unclear what accounts for the inactivity of reducing monomers in light of their biological potency in other systems. It does not seem likely that the reducing NAM itself confers inactivity since the identical structure is present in MDP and at the ends of S-0-PG. S-0-PG decreases food intake and weight gain in both the F344 and Lewis strains of rats. While F344 rats have been shown to be more resistant than Lewis rats to PG-induced arthritis in an in vivo model (1, 55) , this difference is believed to be due to a defective hypothalamic-pituitary-adrenal (HPA) axis response to bacterial cell wall products and IL-1 in Lewis rats (50) . Thus, resistance to cell wall-induced arthritis in F344 rats appears regulated by a functional negative feedback loop involving the HPA axis. On the basis of current data, it appears that the HPA axis may not play a prominent role in regulation of PG-induced hypophagia.
In addition to the difference in susceptibility to arthritis, supernatants from PG-stimulated, thioglycolate-elicited peritoneal macrophages from F344 rats are less potent than Both S-O-PG and MDP fail to elicit a hypophagic response in rats after oral administration, even at doses 20 and 3 times higher, respectively, than doses which are effective when administered i.p. MDP has been documented previously to increase slow-wave sleep in rats after oral administration of the same dose used in the appetite experiment (22) ; therefore, it seems that this route of administration does not destroy bioactivity of the molecule but rather may diminish its access to cells necessary for potentiation of appetite suppression.
We have discounted the possibility that the PG-mediated suppression of appetite is due to contaminating endotoxin by pretreating PG preparations with polymyxin B-agarose and demonstrating that the concentration of residual endotoxin is several orders of magnitude less than that which is required for LPS alone to decrease food intake. Our estimate of 10 ,ug/kg as the minimum hypophagic dose of LPS is within twofold of the minimum effective dose of LPS reported by others (30) and only about twice that of S-O-PG. The similar potencies of LPS and PG as appetite suppressants are striking since, in most other systems studied to date, LPS is by far the more potent. Obviously, various chemical and physical forms of LPS differ widely in biological potency (33) , and some might be considerably more potent than standard O111:B4 LPS. However, it appears that appetite suppression may be one of the rare biological reactions in which PG and LPS have similar potencies.
It is interesting, and perhaps not merely coincidental, that three cardinal features of infection, i.e., fever, enhanced sleep, and decreased appetite, are regulated in the central nervous system at the hypothalamus and involve serotonergic pathways (5, 54) . It is known that the pyrogenic and somnogenic effects of MDP involve serotonin (38) , and MDP has been shown to compete with serotonin for binding to a murine monocytic cell line (46, 47) , brain cells (45) , and myelin basic protein (39) . However, it is unknown at this time if PG modulates appetite via a serotonergic mechanism.
We have not ruled out the possibility that the reason rats are hypophagic after PG administration is because they are merely sleeping more and, hence, eating less. In fact, PG may decrease appetite and increase sleepiness simultaneously via similar mechanisms. We hope to separate the hypophagic and somnogenic effects of PG in future experiments as has been done with tumor necrosis factor (15) .
From the data presented, we conclude that PG decreases food intake and body weight gain in rats when administered i.p. and that neither O-acetylation nor glycosidic linkage of PG fragments is required for activity. These data are consistent with the hypothesis that PG fragments may contribute to loss of appetite during bacterial illness. 
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